GTHX
Closed
G1 Therapeutics Inc
7.15
0.00 (0.00%)
Last Update: 18 Sep 2024 16:30:00
Yesterday: 7.15
Day's Range: 7.15 - 7.15
Send
sign up or login to leave a comment!
When Written:
2.625
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapies for the treatment of cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
G1 Therapeutics' lead product candidate is trilaciclib, a first-in-class myelopreservation agent that is designed to protect bone marrow from damage caused by chemotherapy. Trilaciclib is currently being evaluated in multiple clinical trials for the treatment of small cell lung cancer, triple-negative breast cancer, and colorectal cancer.
The company's pipeline also includes several other product candidates, including rintodestrant, a selective estrogen receptor degrader for the treatment of estrogen receptor-positive breast cancer, and lerociclib, a CDK4/6 inhibitor for the treatment of breast cancer.
G1 Therapeutics has partnerships with several pharmaceutical companies, including Boehringer Ingelheim and Genentech, to develop and commercialize its product candidates. The company went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol GTHX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
G1 Therapeutics' lead product candidate is trilaciclib, a first-in-class myelopreservation agent that is designed to protect bone marrow from damage caused by chemotherapy. Trilaciclib is currently being evaluated in multiple clinical trials for the treatment of small cell lung cancer, triple-negative breast cancer, and colorectal cancer.
The company's pipeline also includes several other product candidates, including rintodestrant, a selective estrogen receptor degrader for the treatment of estrogen receptor-positive breast cancer, and lerociclib, a CDK4/6 inhibitor for the treatment of breast cancer.
G1 Therapeutics has partnerships with several pharmaceutical companies, including Boehringer Ingelheim and Genentech, to develop and commercialize its product candidates. The company went public in 2017 and is listed on the NASDAQ stock exchange under the ticker symbol GTHX.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








